June 14, 2022 -Contract Awarded for Products that Bring Improvement to the Health Care Industry
PITTSBURGH, PA – (June 14, 2022) MolecuLight Corp., the leader in point-of-care fluorescence imaging for the real-time detection of bacteria in wounds, announces it has been awarded a new group purchasing agreement with Premier, Inc. – a
… Read MoreJune 1, 2022 -Authors of International Consensus Suggest that Fluorescence Imaging of Bacterial Burden is Positioned to Change Contemporary Paradigms of Post-Surgical Wound Management
Toronto, CANADA and London, UK – (June 1, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection and localization of elevated bacterial load in wounds, announced
… Read MoreApril 6, 2022 -KOVE Inc. to Distribute the MolecuLight Product Suite to Large South Korean Wound Care Market
Toronto, CANADA and Seoul, SOUTH KOREA – (April 6, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, and KOVE Inc., announce that the MolecuLight
… Read MoreMarch 1, 2022 -Wide-Spread Clinical Evidence using the MolecuLight i:X Platform Reveals its Significant Global Adoption and Proven Utility in Wound Care
Toronto, CANADA and Abu Dhabi, UNITED ARAB EMIRATES – (March 1, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces
… Read MoreFebruary 24, 2022 -8 Clinical Posters and a Presentation and Hands-On Workshop Highlights the Breadth of Clinical Benefits of the MolecuLight Device for Wound Care Applications
Toronto, ONTARIO and Philadelphia, PENNSYLVANIA – (February 24, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads,
… Read MoreJanuary 18, 2022 -Authors Suggest that Fluorescence Imaging of Bacterial Burden is Positioned to Change Contemporary Paradigms of Post-Surgical Wound Management
TORONTO, ONTARIO – (Jan. 18, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication of “Uncovering
… Read MoreJanuary 4, 2022 -
DALLAS, TEXAS and TORONTO, ONTARIO – (Jan. 4, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that SWK Holdings Corporation has provided $10M USD structured debt to support MolecuLight’s global commercial expansion. SWK Holdings Corporation (Nasdaq: SWKH) is
… Read MoreOctober 28, 2021 -7 Clinical Posters and Presentations Highlight the Breadth of Clinical Benefits of the MolecuLight Device for Wound Care Applications
Toronto, ONTARIO and Las Vegas, NEVADA– (October 28, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces the presentation of
… Read MoreOctober 19, 2021 -
Charlotte, NC, and Pittsburgh, PA, October 19, 2021 – Joerns Healthcare, a healthcare technology and equipment services company, announces the addition of the MolecuLight i:X® and DX™ wound imaging platforms to its wound management portfolio through an agreement with MolecuLight Corp. to provide MolecuLight’s fluorescence imaging technology
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2025
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.